文献速递腹部技术与安全CT

仑伐替尼诱导性肠炎的CT影像表现

CT imaging findings of lenvatinib-induced enteritis.
PubMed 文献 · Abdom Radiol (NY) · 2021-03-05

本研究为单中心回顾性研究,纳入58例接受仑伐替尼治疗的不可切除肝细胞癌或甲状腺癌患者,由两名盲法放射科医生评估腹盆腔CT上的肠炎表现。结果显示56.9%患者CT可见肠炎,其中75.8%累及十二指肠空肠;CT肠炎组胃肠道不良事件、腹泻、药物中断及其他不良事件数量均显著高于无肠炎组。

要点

  • 仑伐替尼治疗患者CT上肠炎发生率56.9%,多表现为十二指肠空肠炎。
  • CT肠炎组腹泻发生率60.6%,显著高于无肠炎组的12.0%。
  • CT肠炎与药物中断频率显著相关(75.8% vs 40.0%)。

关键影像表现/征象

  • CT可见肠炎者33/58(56.9%),其中25/33(75.8%)表现为十二指肠空肠炎。

临床应用与阅片要点

  • 接受仑伐替尼治疗的患者,阅片时需关注十二指肠和空肠有无肠炎征象。
  • CT发现肠炎可能提示胃肠道不良事件及治疗中断风险较高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the relationship between abnormal findings on abdomino-pelvic CT and adverse events in oncologic patients treated with lenvatinib, and their relationship with treatment planning.

METHODS: This single institutional retrospective study included 58 patients with unresectable hepatocellular carcinoma or unresectable thyroid carcinoma (mean age ± standard deviation 69.6 ± 10.0 years; range 39-84 years; 48 men) who underwent CT between October 2016 and July 2020. Two radiologists who were blinded to clinical information including the presence or absence of diarrhea evaluated the imaging findings, including the presence/absence of enteritis in each intestinal segment. Gastrointestinal adverse events (diarrhea, decreased appetite, nausea, and vomiting) and other drug-induced adverse events requiring treatment or follow-up during lenvatinib treatment were also investigated. The frequency of these adverse events was compared between the patients with and without enteritis using Fisher's exact test or the Mann-Whitney U test.

RESULTS: Enteritis was found on CT in the majority (33/58 [56.9%]) of the patients, and most of them (25/33 [75.8%]) showed duodenojejunitis. The frequency of gastrointestinal adverse events (28/33 [84.8%] vs. 13/25 [56.0%], p = 0.009), diarrhea (20/33 [60.6%] vs. 3/25 [12.0%], p < 0.001), and drug interruptions (25/33 [75.8%] vs. 10/25 [40.0%], p = 0.008) and the number of other adverse events (3.9 ± 1.7 vs. 2.3 ± 1.3, p < 0.001) were significantly higher in the patients with enteritis on CT than in those without.

CONCLUSIONS: Lenvatinib-induced enteritis frequently involved the duodenum and jejunum and was related to a significantly higher frequency of treatment interruptions and gastrointestinal adverse events.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Kurokawa R, Hagiwara A, Tanishima T, et al. CT imaging findings of lenvatinib-induced enteritis. Abdom Radiol (NY). 2021. PMID: 33674959. doi:10.1007/s00261-021-03006-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。